NeuroVive presents NVP025 mitochondrial myopathy project progress at Mitochondrial Medicine conference
Lund, Sweden, 20 April 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that its mitochondrial myopathy project, NVP025, has been selected for an oral presentation at the prestigious Mitochondrial Medicine 2018 conference held on 9-11 May in Cambridge, UK.The detailed results from an experimental study conducted in collaboration with Professor Håkan Westerblad and his research team at Karolinska Institutet will be presented. The study evaluated the effects of NeuroVive's NVP025 cyclophilin inhibitor in an experimental model of mitochondrial myopathy.